Vallon Pharmaceuticals Continues Advancement of Pivotal Study in Lead Development Program, ADAIR, Toward Potential Approval
April 13, 2021 08:05 ET
|
Vallon Pharmaceuticals Inc.
- Ongoing ADAIR SEAL study on target for pivotal data readout in second half of 2021- Target NDA filing in Q2 2022 for a potential abuse-deterrent alternative to commercially available IR amphetamines...
Park Hotels & Resorts Inc. Reports Fourth Quarter and Full Year 2020 Results
February 25, 2021 16:15 ET
|
Park Hotels & Resorts Inc.
TYSONS, Va., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Park Hotels & Resorts Inc. (“Park” or the “Company”) (NYSE: PK) today announced results for the fourth quarter and full year ended December 31,...
DRGT Completes a Pivotal Phase I Trial; Results Confirm 6X Faster Attainment Of Maximum Plasma Levels For Pain Management Compared To Currently Available COX-2 Inhibitor
June 10, 2019 09:00 ET
|
Druggability Technologies Holdings Ltd
BUDAPEST, Hungary, June 10, 2019 (GLOBE NEWSWIRE) -- Druggability Technologies Holdings (DRGT) today announced results from a pharmacokinetic study of their novel formulation of celecoxib...
CHESAPEAKE LODGING TRUST SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Merger
May 06, 2019 11:52 ET
|
Rigrodsky & Long, P.A.
WILMINGTON, Del., May 06, 2019 (GLOBE NEWSWIRE) -- Rigrodsky & Long, P.A.: Do you own shares of Chesapeake Lodging Trust (NYSE: CHSP)?Did you purchase any of your shares prior to May 6, 2019?Do...
AXIM® Biotech Receives Positive PK Data Results for CanChew Plus® CBD Gum
January 04, 2017 09:00 ET
|
AXIM Biotechnologies, Inc
NEW YORK, Jan. 04, 2017 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, received positive pharmacokinetic (PK)...